INTEGRA LIFESCIENCES HOLDINGS CORP: Invesco Ltd. discloses a stake of more than 5% (Schedule 13G)
Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 10 November 2026, by SEC EDGAR SCHEDULE 13G
30
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Invesco Ltd. disclosed a stake exceeding 5% in Integra LifeSciences Holdings Corp. via a Schedule 13G filing with the SEC (accession 0000914208-26-000418). The passive-investor threshold crossing makes Invesco a notable holder in the medical technology company. The filing did not specify the exact share count or percentage above the 5% line. Investors will watch for further 13G amendments or 13D filings that could signal a more active stance.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Integra Lifesciences Holdings Corp, Invesco Ltd.